August 20, 2019

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In women with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab, pyrotinib plus capecitabine yielded statistically significant better overall response rate and progression-free survival than lapatinib plus capecitabine in this randomized phase II trial.

Me gusta

Guardar

Cite This Study

Ma et al. (Tue,) studied this question.

synapsesocial.com/papers/69dd1ef03ffc04feac1334bd https://doi.org/https://doi.org/10.1200/jco.19.00108

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER22001 · 11,499 citations
2Pyrotinib shows activity in metastatic breast cancer2017 · 30 citations
3Analysis of the cause of discordance between two radiologists on the assessment of radiographic response and progression for subjects enrolled in breast cancer clinical trials employing blinded independent central review.2010 · 3 citations
4Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer2014 · 137 citations
5Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer2013 · 84 citations

Me gusta

Guardar